About Stallergenes Greer
Stallergenes Greer is a Healthcare company based in London (United Kingdom) founded in 2013, and was acquired by Waypoint Capital in March 2019. Allergen immunotherapies for respiratory allergies are developed. Stallergenes Greer has completed 1 acquisition, including Adeo Health Science. Its chief executive, as recorded, is Michele Antonelli. Its website stallergenesgreer.com draws about 13 thousand monthly visits. Stallergenes Greer offers products and services including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Prophylactic. Its legal entity is STALLERGENES GREER LTD.
Company details
Stallergenes Greer is developing allergen immunotherapy (vaccine) for respiratory allergies. Its drug pipeline STAGR 320 (HDM) for Allergic Rhinitis (Phase 3 in EuropeUS and approved in Japan) and for HDM) Allergic Asthma (Phase 2); STAGR 120 for (Jap.Cedar) Allergic Rhinitis (Phase 2); JPSTAGR SAIL SLIT(Ragweed) Allergic Rhinitis (Phase 3)
- Headquarters London, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website stallergenesgreer.com
- Social LinkedIn X Facebook YouTube
- Acquired by Waypoint Capital (Mar 2019)
- Legal Name Stallergenes Greer Ltd
- Date of Incorporation 06 Dec, 2013
- Jurisdiction LONDON, UNITED KINGDOM
- Investors
- Investments & Acquisitions
- Acquired by
Products & Services of Stallergenes Greer
Stallergenes Greer offers a comprehensive portfolio of products and services, including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine.
Therapy to desensitize patients against allergens for better allergy control.
Methods for identifying allergens in respiratory and food allergies.
Tailored treatments addressing unmet needs in allergy care globally.
Apps and channels of Stallergenes Greer
its YouTube channel Stallergenes Greer has 1.46K subscribers and 30 videos.
Videos from Stallergenes Greer
The most watched videos on Stallergenes Greer's YouTube channel, Stallergenes Greer (1.46K subscribers). Click a video to play it here.
More on Stallergenes Greer.
Investors in Stallergenes Greer
Stallergenes Greer has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include B-FLEXION.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
B-FLEXION is recognized as a private entrepreneurial investment firm. | waypointcapital.net |
Investor details for Stallergenes Greer
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Stallergenes Greer
61 people are tracked at Stallergenes Greer (21 in leadership, 2 in board & advisors, 38 in team).
| Name | Role | Group |
|---|---|---|
Michele Antonelli | CEO | Leadership |
Nicola Lamacchia | Chief Financial Officer | Leadership |
Tibor Nemes | EVP, Head of Americas | Leadership |
Adam Haithcox | Director, Business Systems | Leadership |
Andy Möckel | Vice President Commercial Operations D-a-ch Region/ Geschäftsführer D-a-ch Region | Leadership |
Christian Doering | Director Pharmaceutical Operations (dach) | Leadership |
Marc Valentin | Director Market Access DACH & Eu/international Region | Leadership |
Jennifer Hryniw | General Manager | Leadership |
Melissa A. Schmidt | Vice President, Legal And People Ops Americas | Leadership |
Stefania Sara Biolcati | Finance Director South Europe (italy, Spain & Portugal) | Leadership |
Matthew Elfeldt | Vice President Of Commercial Operations | Leadership |
Trace Little | Director Of Procurement | Leadership |
Stephane Lebarbier | Global Head Of Procurement | Leadership |
William Mahoney | Vice President, Global Strategic Sourcing | Leadership |
Nicole Carfagnini | Head Of Marketing (us) - Food Allergy | Leadership |
Jacques Dysli | Global Head Of Performance & Portfolio | Leadership |
Marek Borovsky | General Manager | Leadership |
Catherine Kress | VP Communications | Leadership |
Stephanie Lauchet | Global PMO Director | Leadership |
Alexandra Hess | Head Of Site Controlling | Leadership |
41 more people are available in the full profile.
Complete people profiles for Stallergenes Greer
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stallergenes Greer
Stallergenes Greer has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Adeo Health Science.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufactures proprietary baby food to safely introduce eight allergens. | adeohealth.com | Boston, United States | 2017 | May 2019 | •••• |
Complete acquisition details for Stallergenes Greer
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Stallergenes Greer
5 dated milestones of Stallergenes Greer across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Stallergenes Greer is founded.
- Exit Acquired by Waypoint Capital.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Waypoint Capital.
- Acquisition Acquires Adeo Health Science.
Web traffic of Stallergenes Greer
The website of Stallergenes Greer (stallergenesgreer.com) receives about 13.4K visits a month and ranks #1,596,150 among all websites worldwide, #2,149 in Biotechnology and Pharmaceuticals.
- Monthly visits13.4K
▼ 8.9% vs previous month
- Unique visitors5.9K
per month
- Global rank#1,596,150
among all websites
- Category rank#2,149
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.1
- Average visit41 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Stallergenes Greer. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alk.net | 100% | 43.7K | #855,421 | View details | |
mein-allergie-portal.com | mein-allergie-portal.com | 64% | #455,429 | – | |
| daab.de | 54% | 74.6K | #477,513 | View details | |
stagrallergy.com | stagrallergy.com | 29% | #4,744,016 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stallergenes Greer
Complete news archive for Stallergenes Greer
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stallergenes Greer
Stallergenes Greer was founded in 2013.
Stallergenes Greer is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Michele Antonelli is the CEO of Stallergenes Greer, as recorded in our data.
Stallergenes Greer is developing allergen immunotherapy (vaccine) for respiratory allergies. Its drug pipeline STAGR 320 (HDM) for Allergic Rhinitis (Phase 3 in EuropeUS and approved in Japan) and for HDM) Allergic Asthma (Phase 2); STAGR 120 for (Jap.Cedar) Allergic Rhinitis (Phase 2); JPSTAGR SAIL SLIT(Ragweed) Allergic Rhinitis (Phase 3).
Stallergenes Greer offers Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine.
Stallergenes Greer has made 1 acquisition, including Adeo Health Science.
Stallergenes Greer has 1 investor. Key investors include B-FLEXION.
Stallergenes Greer operates through Stallergenes Greer Ltd.
Yes. Stallergenes Greer was acquired by Waypoint Capital in March 2019.

